Liminatus Pharma explores digital asset treasury strategy

Liminatus Pharma, Inc. (NASDAQ: LIMN) announced it has initiated a strategic review to evaluate the potential inclusion of regulated digital asset strategies in its treasury management framework.

The preclinical-stage biopharmaceutical company, which develops targeted cancer immunotherapies, said the review is part of its treasury management and balance sheet optimization efforts. The company emphasized that its core focus remains on advancing cancer therapies.

"Liminatus remains fully committed to our mission of developing life-changing cancer therapies," said Chris Kim, CEO of Liminatus Pharma. "This review is not a shift in our business focus, but an effort to evaluate modern financial tools—such as regulated digital assets—that may enhance the way we manage non-operating capital."

The company stated this is an exploratory process and has not entered into any agreements regarding the acquisition, custody, or use of digital assets. Any potential future steps would require approval by the Board of Directors and compliance with Securities and Exchange Commission regulations and public company disclosure standards.

Liminatus is based in La Palma, California, and develops immunotherapies for cancer patients. The company is advancing a pipeline of therapies targeting cancer antigens and tumor-specific immune responses.

You May Also Be Interested In

• NOG boosts share repurchase program to $243M, reiterates 2026 guidance
• Plug Power sells Texas project, restructures New York deal with Stream
• Evaxion shares preclinical data for CMV vaccine program EVX-V1